Why McKesson (MCK) is a Top Value Stock for the Long-Term

McKesson (MCK) is positioned as a strong investment, evidenced by its Zacks #2 (Buy) Rank and top 'A' ratings for both its Value and VGM Style Scores. The healthcare services firm exhibits attractive valuation with a 19.31 forward P/E, further supported by recent analyst upgrades for fiscal 2026 earnings, which saw the Zacks Consensus Estimate rise by $0.67 to $37.25 per share. These factors, coupled with a 3.9% average earnings surprise, suggest MCK warrants investor consideration.

Analysis

McKesson Corporation (MCK) presents a compelling investment case based on a combination of positive analyst sentiment and attractive valuation metrics, as highlighted by the Zacks rating system. The company secures a #2 (Buy) rank, which is further supported by an 'A' grade for both its overall VGM (Value, Growth, Momentum) score and its specific Value Style Score. This valuation thesis is quantified by a forward P/E ratio of 19.31. The bullish outlook is substantiated by a significant trend in earnings estimate revisions, with eight analysts raising their forecasts for fiscal 2026 in the last 60 days. This consensus has pushed the fiscal 2026 earnings per share estimate up by $0.67 to $37.25. Reinforcing this positive outlook, MCK has a consistent history of outperformance, delivering an average positive earnings surprise of 3.9%.

Key Decisions for Investors

• Value-oriented investors may find MCK's valuation compelling, supported by its forward P/E of 19.31 and a top-rated 'A' Value Score.
• The strong upward trend in earnings estimates, with eight analysts raising fiscal 2026 forecasts, signals growing confidence in future profitability and should be a key factor for consideration.
• Given the combination of a 'Buy' rating, strong quantitative scores, and a history of earnings beats, MCK warrants consideration for an investor's shortlist, particularly for those with a long-term investment horizon.